Ajanta Pharma, Dishman Pharmaceuticals and Chemicals, Divi’s Laboratories, Piramal Enterprises, Strides Arcolab, Divi’s Laboratories, Lupin, Cipla, Dr Reddy’s Laboratories and Sun Pharmaceutical Industries are up 2%-5% each on the NSE.
At 03:02 PM, the CNX Pharma index was up 2.3% or 279 points at 13,219 compared to a 0.20% decline in CNX Nifty.
Strides Arcolab have moved higher by 3% to Rs 1,231 after announcing that it achieved closure of transaction for acquisition of a generic pharmaceutical business in Australia and related assets from Aspen.
The acquired business will be integrated and consolidated with Strides effective September 1, 2015, Strides Arcolab added.
Lupin was up 4% at Rs 1,937 on the BSE. The stock has rallied by 7% in the past three trading sessions, from Rs 1,812, after the drug co0mpany received approval from US health regulator USFDA to market generic Omeprazole delayed-release capsules used to treat ulcer in the American market.
The company has received final approval for its Omeprazole delayed-release capsules (40 mg) from the United States Food and Drugs Administration (USFDA), Lupin Ltd said in a statement.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)